Corrigendum to “TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain” [Biochem. Pharmacol. 192 (2021) 114688] (Biochemical Pharmacology (2021) 192, (S0006295221003014), (10.1016/j.bcp.2021.114688))

Moses M. Kasembeli, Pooja Singhmar, Jiacheng Ma, Jules Edralin, Yongfu Tang, Clydell Adams, Cobi J. Heijnen, Annemieke Kavelaars, David J. Tweardy

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors of this paper would like to point out that the ‘Declaration of Competing Interest’ statement omitted the following text: “David Tweardy receives compensation as a member of Tvardi Therapeutics’ scientific advisory board and also holds equity in the company.” The authors apologise for this error.

Original languageEnglish (US)
Article number114860
JournalBiochemical Pharmacology
Volume195
DOIs
StatePublished - Jan 2022
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Fingerprint

Dive into the research topics of 'Corrigendum to “TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain” [Biochem. Pharmacol. 192 (2021) 114688] (Biochemical Pharmacology (2021) 192, (S0006295221003014), (10.1016/j.bcp.2021.114688))'. Together they form a unique fingerprint.

Cite this